Dasatinib
- Generic Name
- Dasatinib
- Brand Names
- Sprycel
- Drug Type
- Small Molecule
- Chemical Formula
- C22H26ClN7O2S
- CAS Number
- 302962-49-8
- Unique Ingredient Identifier
- X78UG0A0RN
- Background
Dasatinib is an orally available multikinase inhibitor indicated for the treatment of Philadelphia chromosome (Ph)-positive leukemias. Ph is a chromosomal abnormality found in patients with chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL), where the ABL tyrosine kinase and the breakpoint cluster region (BCR) gene transcribe the chimeri...
- Indication
Dasatinib is indicated for the treatment of newly diagnosed adults with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase, as well as adults with chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy including imatinib, and adults with Philadelphia chromosome-posi...
- Associated Conditions
- Accelerated Phase Chronic Myelogenous Leukemia (CML), Acute Lymphoblastic Leukaemias (ALL), Chronic Phase Chronic Myeloid Leukemia, Blast phase Chronic myeloid leukemia
- Associated Therapies
- -
Dasatinib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Did Not Respond to Imatinib Mesylate
- Conditions
- Accelerated Phase Chronic Myelogenous LeukemiaBlastic Phase Chronic Myelogenous LeukemiaChildhood Chronic Myelogenous LeukemiaChronic Myelogenous Leukemia, BCR-ABL1 PositiveMeningeal Chronic Myelogenous LeukemiaRecurrent Childhood Acute Lymphoblastic LeukemiaRelapsing Chronic Myelogenous LeukemiaUnspecified Childhood Solid Tumor, Protocol Specific
- Interventions
- First Posted Date
- 2006-04-21
- Last Posted Date
- 2013-02-05
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 48
- Registration Number
- NCT00316953
- Locations
- 🇺🇸
Children's Oncology Group, Arcadia, California, United States
Study of Dasatinib in Children and Adolescents With Relapsed or Refractory Leukemia
- First Posted Date
- 2006-03-23
- Last Posted Date
- 2021-02-26
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 63
- Registration Number
- NCT00306202
- Locations
- 🇬🇧
Local Institution, Birmingham, West Midlands, United Kingdom
A Study of Dasatinib in Patients With Chronic Myelogenous Leukemia Who Are Resistant or Intolerant of Imatinib Mesylate
- Conditions
- Interventions
- First Posted Date
- 2006-03-06
- Last Posted Date
- 2010-02-08
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 400
- Registration Number
- NCT00298987
- Locations
- 🇨🇦
Local Institution, Montreal, Quebec, Canada
Dasatinib in Treating Patients With Early Chronic Phase Chronic Myelogenous Leukemia
- Conditions
- Interventions
- First Posted Date
- 2005-11-16
- Last Posted Date
- 2024-06-12
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 156
- Registration Number
- NCT00254423
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Chronic Myelogenous Leukemia (CML) - Follow on: Study of BMS-354825 in Subjects With CML
- First Posted Date
- 2005-07-25
- Last Posted Date
- 2016-08-25
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 724
- Registration Number
- NCT00123474
- Locations
- 🇺🇸
Kaiser Permanente Medical Center, Vallejo, California, United States
🇺🇸University Of Maryland, Baltimore, Maryland, United States
🇺🇸Western Pennsylvania Cancer Institute, Pittsburgh, Pennsylvania, United States
Advanced Chronic Myelogenous Leukemia (CML) - Follow On: Study of BMS-354825 in Subjects With CML
- Conditions
- Interventions
- First Posted Date
- 2005-07-25
- Last Posted Date
- 2014-11-02
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 638
- Registration Number
- NCT00123487
- Locations
- 🇺🇸
The University Of North Carolina At Chapel Hill, Chapel Hill, North Carolina, United States
🇺🇸Washington University School Of Medicine, Saint Louis, Missouri, United States
🇺🇸Emory University School Of Medicine, Atlanta, Georgia, United States
BMS-354825 or Imatinib Mesylate in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Did Not Respond to Previous Imatinib Mesylate
- Conditions
- First Posted Date
- 2005-06-03
- Last Posted Date
- 2011-06-07
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Registration Number
- NCT00112775
- Locations
- 🇺🇸
Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, California, United States
Dasatinib (BMS-354835) Versus Imatinib Mesylate in Subjects With Chronic Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2005-02-16
- Last Posted Date
- 2010-08-10
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 150
- Registration Number
- NCT00103844
- Locations
- 🇬🇧
Local Institution, Newcastle, Tyne and Wear, United Kingdom
BMS-354825 in Patients With Chronic Accelerated, or Blast Phase Chronic Myelogenous Leukemia or Philadelphia Positive Acute Lymphoblastic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2005-02-15
- Last Posted Date
- 2011-04-14
- Lead Sponsor
- Bristol-Myers Squibb
- Registration Number
- NCT00103701
- Locations
- 🇺🇸
Local Institution, Houston, Texas, United States
Dasatinib (BMS-354825) in Subjects With Myeloid Blast Phase Chronic Myeloid Leukemia Resistant to or Intolerant of Imatinib Mesylate
- First Posted Date
- 2005-01-14
- Last Posted Date
- 2010-08-10
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 124
- Registration Number
- NCT00101816
- Locations
- 🇬🇧
Local Institution, London, Greater London, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.